| Primary |
| Acute Lymphocytic Leukaemia |
15.0% |
| Diffuse Large B-cell Lymphoma |
10.1% |
| Breast Cancer |
8.8% |
| B-cell Lymphoma |
8.3% |
| Mantle Cell Lymphoma |
6.2% |
| Hodgkin's Disease |
6.1% |
| Plasma Cell Myeloma |
6.1% |
| Bone Sarcoma |
5.0% |
| Non-hodgkin's Lymphoma |
4.5% |
| Ewing's Sarcoma |
4.2% |
| Prophylaxis |
4.1% |
| Product Used For Unknown Indication |
4.0% |
| Neuroblastoma |
3.1% |
| Burkitt's Lymphoma |
2.5% |
| Peripheral T-cell Lymphoma Unspecified |
2.4% |
| Sarcoma |
2.1% |
| T-cell Lymphoma |
2.0% |
| Premedication |
1.9% |
| Lymphoma |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.7% |
|
| Off Label Use |
29.7% |
| Vomiting |
10.1% |
| Thrombocytopenia |
6.7% |
| Toxicity To Various Agents |
6.7% |
| Sepsis |
5.9% |
| Neutropenia |
4.9% |
| Myelodysplastic Syndrome |
4.4% |
| Death |
4.0% |
| Pneumonia |
3.2% |
| Wrong Technique In Drug Usage Process |
3.2% |
| Traumatic Lung Injury |
2.9% |
| Febrile Neutropenia |
2.5% |
| Infection |
2.3% |
| Hepatitis B |
2.1% |
| Renal Failure |
2.1% |
| Respiratory Failure |
2.1% |
| Neuropathy Peripheral |
1.9% |
| Pancytopenia |
1.9% |
| Pyrexia |
1.9% |
| Cardiotoxicity |
1.7% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
21.4% |
| Product Used For Unknown Indication |
10.5% |
| Acute Lymphocytic Leukaemia |
10.0% |
| Breast Cancer |
8.5% |
| B-cell Lymphoma |
6.8% |
| Non-hodgkin's Lymphoma |
5.9% |
| Hodgkin's Disease |
5.0% |
| Prophylaxis |
3.9% |
| Chromosome Analysis Abnormal |
3.7% |
| Lymphoma |
3.2% |
| Mantle Cell Lymphoma |
3.1% |
| Sarcoma |
2.8% |
| Drug Use For Unknown Indication |
2.5% |
| Peripheral T-cell Lymphoma Unspecified |
2.2% |
| Plasma Cell Myeloma |
2.1% |
| Ewing's Sarcoma |
2.1% |
| Burkitt's Lymphoma |
1.8% |
| Neoplasm Malignant |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.5% |
| Bone Sarcoma |
1.4% |
|
| Death |
10.8% |
| Febrile Neutropenia |
9.6% |
| Drug Exposure During Pregnancy |
7.1% |
| Thrombocytopenia |
7.1% |
| Vomiting |
6.4% |
| Off Label Use |
6.1% |
| Neutropenia |
5.0% |
| Sepsis |
4.8% |
| Pneumonia |
4.7% |
| Myelodysplastic Syndrome |
4.3% |
| Infection |
4.1% |
| Pyrexia |
4.1% |
| Disease Progression |
3.7% |
| Neutropenic Infection |
3.7% |
| Toxicity To Various Agents |
3.7% |
| Pulmonary Embolism |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Malaise |
2.9% |
| Mucosal Inflammation |
2.3% |
| Venous Thrombosis |
2.2% |
|
| Concomitant |
| Non-hodgkin's Lymphoma |
15.0% |
| Product Used For Unknown Indication |
11.4% |
| Diffuse Large B-cell Lymphoma |
10.1% |
| B-cell Lymphoma |
8.7% |
| Breast Cancer |
7.1% |
| Drug Use For Unknown Indication |
6.3% |
| Lymphoma |
5.5% |
| Multiple Myeloma |
4.4% |
| Chemotherapy |
3.8% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Plasma Cell Myeloma |
3.4% |
| Chronic Lymphocytic Leukaemia |
3.4% |
| Breast Cancer Metastatic |
3.3% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
2.8% |
| Prophylaxis |
2.7% |
| Mantle Cell Lymphoma |
2.1% |
| Prophylaxis Of Nausea And Vomiting |
1.8% |
| T-cell Lymphoma |
1.7% |
| Hodgkin's Disease |
1.5% |
| Burkitt's Lymphoma |
1.2% |
|
| Death |
12.9% |
| Disease Progression |
8.6% |
| Thrombocytopenia |
7.9% |
| Vomiting |
7.6% |
| Sepsis |
6.3% |
| No Adverse Event |
6.0% |
| Weight Decreased |
5.6% |
| Febrile Neutropenia |
5.3% |
| Toxicity To Various Agents |
5.0% |
| Neutropenia |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Pulmonary Embolism |
3.6% |
| Drug Ineffective |
3.3% |
| Progressive Multifocal Leukoencephalopathy |
3.3% |
| Somnolence |
3.3% |
| Encephalopathy |
3.0% |
| Renal Failure Acute |
2.6% |
| Respiratory Failure |
2.6% |
| Thrombosis |
2.6% |
| Acute Myeloid Leukaemia |
2.3% |
|
| Interacting |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
51.4% |
| Ewing's Sarcoma |
22.9% |
| Oral Candidiasis |
11.4% |
| Breast Cancer Metastatic |
5.7% |
| Prophylaxis Of Nausea And Vomiting |
5.7% |
| Prophylaxis |
2.9% |
|
| Neuropathy Peripheral |
28.6% |
| Renal Impairment |
28.6% |
| Leukopenia |
14.3% |
| Neutropenia |
14.3% |
| Vomiting |
14.3% |
|
